Cite
HARVARD Citation
Bravo, F. et al. (2021). Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up. Clinical and translational gastroenterology. 12 (2), pp. e00298-. [Online].